会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • USER INTERFACE FOR HANDWRITING INPUTS
    • 用户界面进行手写输入
    • WO2012159243A1
    • 2012-11-29
    • PCT/CN2011/074387
    • 2011-05-20
    • MICROSOFT CORPORATIONDAI, JuanZHOU, YiGONG, XinCHEN, Liang
    • DAI, JuanZHOU, YiGONG, XinCHEN, Liang
    • G06F3/041
    • G06K9/00436G06F3/018G06F3/04883
    • A method, medium, device, and user interface are provided for receiving a handwriting input and for presenting prediction candidates based on the handwriting input. A pen down event is detected in a writing panel of a user interface. The writing panel is expanded to overlie function keys and a candidate window of the user interface such that those features are made inaccessible for inadvertent selections thereof. Upon detection of a pen up event the writing panel is decreased in size to again reveal the features. Recognition candidates are identified based on the handwriting input. Prediction candidates are also identified based on a highest ranking recognition candidate and are presented in combination with the highest ranking recognition candidate. Prediction candidates are thereby identifiable with the recognition candidate with which they are associated and selection of a prediction candidate and recognition candidate may be performed in single selection input.
    • 提供了一种方法,媒体,设备和用户界面,用于接收手写输入并基于手写输入呈现预测候选。 在用户界面的书写面板中检测到笔直事件。 写入面板被扩展以覆盖用户界面的功能键和候选窗口,使得这些特征使得无意识地进行选择。 当检测到笔触事件时,写入面板的尺寸减小以再次显示特征。 基于手写输入识别识别候选者。 预测候选者也基于最高排名识别候选来确定,并且与最高排名的识别候选者一起呈现。 因此,预测候选者可以与其相关联的识别候选者识别,并且可以在单选输入中执行预测候选和识别候选的选择。
    • 3. 发明申请
    • DISPLAYING AND INPUTTING SYMBOLS
    • 显示和输入符号
    • WO2012159246A1
    • 2012-11-29
    • PCT/CN2011/074399
    • 2011-05-20
    • MICROSOFT CORPORATIONZHANG, FangCHE, ChiweiGONG, Xin
    • ZHANG, FangCHE, ChiweiGONG, Xin
    • G06F3/048
    • G06F3/018G06F3/0236G06F3/0237
    • Methods, systems, devices, and computer-storage media having computer- usable instructions embodied thereon, for displaying and inputting symbols are provided. Bopomofo symbols are phonetic representations of Chinese characters. To accommodate all the Bopomofo symbols on a mobile device keyboard without sacrificing key size, the Bopomofo keys are dynamically disabled based on grammar rules and user inputs. For example, a symbol that is not eligible to follow an input symbol is disabled such that it does not distract a user searching for a symbol in the keyboard. Further, specific keys on a keyboard are dynamically replaced with tone keys once a user inputs a symbol. A user interface for displaying the symbols is, thus, consistent and easy to navigate for a user.
    • 提供了其上包含有计算机可用指令的方法,系统,设备和计算机存储介质,用于显示和输入符号。 Bopomofo符号是汉字的语音表示。 为了在移动设备键盘上容纳所有Bopomofo符号,而不牺牲密钥大小,Bopomofo密钥根据语法规则和用户输入动态禁用。 例如,不符合输入符号的符号被禁用,使得它不会分散用户搜索键盘中的符号。 此外,一旦用户输入符号,键盘上的特定键被音频键动态地替换。 因此,用于显示符号的用户界面对于用户而言是一致且易于导航的。
    • 4. 发明申请
    • ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF
    • 抗增生化合物,组合物及其使用方法
    • WO2007002912A3
    • 2007-06-28
    • PCT/US2006025726
    • 2006-06-29
    • GILEAD SCIENCES INCCHENG XIAOQINCOOK GARY PDESAI MANOJ CDOERFFLER EDWARDHE GONG-XINKIM CHOUNG ULEE WILLIAM AROHLOFF JOHN CWANG JIANYINGYANG ZHENG-YU
    • CHENG XIAOQINCOOK GARY PDESAI MANOJ CDOERFFLER EDWARDHE GONG-XINKIM CHOUNG ULEE WILLIAM AROHLOFF JOHN CWANG JIANYINGYANG ZHENG-YU
    • C07F9/6561A61K31/66A61K31/675A61P31/12
    • C07F9/65616Y02P20/55
    • Compounds and compositions of Formula I are described, useful as anti-proliferative agents, and in particular anti-HPV, wherein: Y 1A and Y 1B are independently Y 1 ; R X1 is R X ; R X2 is alkenyl of 2 to 18 carbon atoms or alkynyl of 2 to 18 carbon atoms; Y 1 is = O, -O(R X ), =S, -N(R X ), -N(O)(R X ), -N(OR X ), -N(O)(OR X ), or -N(N(R X )(R X )); R X is independently R 1 , R 2 , R 4 , W 3 , or a protecting group; R 1 is independently -H or alkyl of 1 to 18 carbon atoms; R 2 is independently R 3 or R 4 wherein each R 4 is independently substituted with 0 to 3 R 3 groups or taken together at a carbon atom, two R 2 groups form a ring of 3 to 8 carbons and the ring may be substituted with 0 to 3 R 3 groups; R 3 is R 3a , R 3b , R 3c or R 3d , provided that when R 3 is bound to a heteroatom, then R 3 is R 3c or R 3d ; R 3a is -H, -F, -Cl, -Br, -I, -CF 3 , -CN, N 3 , -NO 2 or -OR 4 ; R 3b is = O, -O(R 4 ), =S, -N(R 4 ), -N(O)(R 4 ), -N(OR 4 ), -N(O)(OR 4 ), or -N(N(R 4 )(R 4 )); 3c is -R 4 , -N(R 4 )(R 4 ), -SR 4 , -S(O)R 4 , -S(O) 2 R 4 , -S(O)(OR 4 ), -S(O) 2 (OR 4 ), -OC(R 3b )R 4 , -OC(R 3b )OR 4 , -OC(R 3b )(N(R 4 )(R 4 )), -SC(R 3b )R 4 , -SC(R 3b )OR 4 , -SC(R 3b )(N(R 4 )(R 4 )), -N(R 4 )C(R 3b )R 4 , -N(R 4 )C(R 3b )OR 4 , -N(R 4 )C(R 3b )(N(R 4 )(R 4 )), W 3 or -R 5 W 3 ; R 3d is -C(R 3b )R 4 , -C(R 3b )OR 4 , -C(R 3b )W 3 , -C(R 3b )OW 3 or -C(R 3b )(N(R 4 )(R 4 )); R 4 is -H, or an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms; R 5 is alkylene of 1 to 18 carbon atoms, alkenylene of 2 to 18 carbon atoms, or alkynylene of 2 to 18 carbon atoms; W 3 is W 4 or W 5 ; W 4 is R 6 , -C(R 3b )R 6 , -C(R 3b )W 5 , -SO M2 R 6 , or -SO M2 W 5 , wherein R 6 is R 4 wherein each R 4 is substituted with O to 3 R 3 groups; W 5 is carbocycle or heterocycle wherein W 5 is independently substituted with O to 3 R 2 groups; and M2 is 0, 1 or 2; or pharmaceutically acceptable salts thereof.
    • 描述了式I的化合物和组合物,其可用作抗增殖剂,特别是抗HPV,其中:Y 1A和Y 1B独立地为Y, 1 ; R X1是R X; R 2 X 2是2至18个碳原子的链烯基或2至18个碳原子的炔基; Y 1是= O,-O(R X),= S,-N(R X)X - , - N(O)( N(O,X),-N(O)(OR X)或-N(N(R' SUP> X )(R X )); R X独立地为R 1,R 2,R 4,W 3, ,或保护基团; R 1独立地是-H或1至18个碳原子的烷基; R 2独立地是R 3或R 4,其中每个R 4独立地被0至3个R 3取代, SUP> 3个或3个碳原子一起取代,2个R 2基团形成3〜8个碳环,该环可以被0〜3个R 3 组 R 3是R 3a,R 3b,R 3c或R i,R 3, 条件是当R 3与杂原子结合时,R 3是R 3c或R 3d; R 3a是-H,-F,-Cl,-Br,-I,-CF 3,-CN,N 3 - , - NO 2或-OR 4; R 3是= O,-O(R 4),= S,-N(R 4), - N(O)( (OR 4),-N(OR 4), - N(O)(OR 4)或-N(N(R' SUP> 4 )(R 4 )); (S 4),-S(R 4),-SR 4,-S(R 4) 4,-S(O)R 4,-S(O)2 R 4,-S(O)( 或(S)4),-S(O)2(OR 4),-OC(R 3b)R -OC(R 3b)或OR 4,-OC(R 3b)(N(R 3) (R 4)),-SC(R 3b)R 4,-SC(R SUP) (R 3)(R 4)(R 4)(R 4) /(S)S),-N(R 4)S(R 3b)R 4,-N(R 4) C(R 3b)或者4,-N(R 4)C(R 3) )(N(R 4)(R 4)),W 3或-R 5 W > 3 ; R 3 d 3是-C(R 3b)R 4,-C(R 3b)或 - -C(R 3b)W 3,-C(R 3b)OW 3 O, >或-C(R 3b)(N(R 4))(R 4)); R 4是-H或1至18个碳原子的烷基,2至18个碳原子的烯基或2至18个碳原子的炔基; R 5是1至18个碳原子的亚烷基,2至18个碳原子的亚烯基或2至18个碳原子的亚炔基; W 3或W 5是W 4或W 5; R 4是R 6,-C(R 3b)R 6,-C(R'), 或3个或更多个,其中,R 1,R 2,R 3,R 5, 其中R 6是R 4,其中每个R 4被0至3个R 3取代, / SUP>组 W 5是碳环或杂环,其中W 5独立地被O至3个R 2基团取代; M2为0,1或2; 或其药学上可接受的盐。
    • 6. 发明申请
    • ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF
    • 抗增殖化合物,组合物及其使用方法
    • WO2007002912A2
    • 2007-01-04
    • PCT/US2006/025726
    • 2006-06-29
    • GILEAD SCIENCES, INC.CHENG, XiaoqinCOOK, Gary, P.DESAI, Manoj, C.DOERFFLER, EdwardHE, Gong-xinKIM, Choung, U.LEE, William, A.ROHLOFF, John, C.WANG, JianyingYANG, Zheng-Yu
    • CHENG, XiaoqinCOOK, Gary, P.DESAI, Manoj, C.DOERFFLER, EdwardHE, Gong-xinKIM, Choung, U.LEE, William, A.ROHLOFF, John, C.WANG, JianyingYANG, Zheng-Yu
    • C07F9/6561A61P31/12A61K31/66
    • C07F9/65616Y02P20/55
    • Compounds and compositions of Formula I are described, useful as anti-proliferative agents, and in particular anti-HPV, wherein: Y 1A and Y 1B are independently Y 1 ; R X1 is R X ; R X2 is alkenyl of 2 to 18 carbon atoms or alkynyl of 2 to 18 carbon atoms; Y 1 is = O, -O(R X ), =S, -N(R X ), -N(O)(R X ), -N(OR X ), -N(O)(OR X ), or -N(N(R X )(R X )); R X is independently R 1 , R 2 , R 4 , W 3 , or a protecting group; R 1 is independently -H or alkyl of 1 to 18 carbon atoms; R 2 is independently R 3 or R 4 wherein each R 4 is independently substituted with 0 to 3 R 3 groups or taken together at a carbon atom, two R 2 groups form a ring of 3 to 8 carbons and the ring may be substituted with 0 to 3 R 3 groups; R 3 is R 3a , R 3b , R 3c or R 3d , provided that when R 3 is bound to a heteroatom, then R 3 is R 3c or R 3d ; R 3a is -H, -F, -Cl, -Br, -I, -CF 3 , -CN, N 3 , -NO 2 or -OR 4 ; R 3b is = O, -O(R 4 ), =S, -N(R 4 ), -N(O)(R 4 ), -N(OR 4 ), -N(O)(OR 4 ), or -N(N(R 4 )(R 4 )); 3c is -R 4 , -N(R 4 )(R 4 ), -SR 4 , -S(O)R 4 , -S(O) 2 R 4 , -S(O)(OR 4 ), -S(O) 2 (OR 4 ), -OC(R 3b )R 4 , -OC(R 3b )OR 4 , -OC(R 3b )(N(R 4 )(R 4 )), -SC(R 3b )R 4 , -SC(R 3b )OR 4 , -SC(R 3b )(N(R 4 )(R 4 )), -N(R 4 )C(R 3b )R 4 , -N(R 4 )C(R 3b )OR 4 , -N(R 4 )C(R 3b )(N(R 4 )(R 4 )), W 3 or -R 5 W 3 ; R 3d is -C(R 3b )R 4 , -C(R 3b )OR 4 , -C(R 3b )W 3 , -C(R 3b )OW 3 or -C(R 3b )(N(R 4 )(R 4 )); R 4 is -H, or an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms; R 5 is alkylene of 1 to 18 carbon atoms, alkenylene of 2 to 18 carbon atoms, or alkynylene of 2 to 18 carbon atoms; W 3 is W 4 or W 5 ; W 4 is R 6 , -C(R 3b )R 6 , -C(R 3b )W 5 , -SO M2 R 6 , or -SO M2 W 5 , wherein R 6 is R 4 wherein each R 4 is substituted with O to 3 R 3 groups; W 5 is carbocycle or heterocycle wherein W 5 is independently substituted with O to 3 R 2 groups; and M2 is 0, 1 or 2; or pharmaceutically acceptable salts thereof.
    • 描述了式I的化合物和组合物,其可用作抗增殖剂,特别是抗HPV,其中:Y 1A和Y 1B表示抗体, sup独立地是Y 1 ; R X1是R X; R X2是2至18个碳原子的链烯基或2至18个碳原子的炔基; Y 1 = O,-O(R X),= S,-N(R X), - N(O)( -N(OR X),-N(O)(OR X)或-N(N(R X) SUP> X )(R X )); R X独立地为R 1,R 2,R 4,W 3,R 4,R 4,R 4, ,或保护基团; R 1独立地为-H或1-18个碳原子的烷基; R 2独立地为R 3或R 4,其中每个R 4独立地被0至3个R 4取代, 两个R 2基团形成3至8个碳原子的环并且该环可以被0至3个R 3取代 组; R 3是R 3a,R 3b,R 3c或R 3d,其中R 3a, 条件是当R 3 3与一个杂原子结合时,则R 3是R 3c或R 3d; R 3a是-H,-F,-Cl,-Br,-I,-CF 3,-CN,N 3, - NO <2>或-OR <4>; (R 4), - N(R 4), - N(O)( -N(OR 4), - N(O)(OR 4)或-N(N(R 4) SUP> 4 )(R 4 )); 3c是-R 4,-N(R 4)(R 4),-SR 5, (O)R 4,-S(O)2 R 4,-S(O)( OR 4),-S(O)2(OR 4),-OC(R 3b)R (R(R 3)4,-OC(R 3b)OR 4,-OC(R 3b) (R 4)),-SC(R 3b)R 4,-SC(R sup) (R(R 4))(R 4)(R 4)R 4(R 4) -N(R 4)C(R 3b)R 4,-N(R 4) (R 3b)OR 4,-N(R 4)C(R 3b) )(N(R 4)(R 4))),W 3或-R 5 W 3 ; R 3d为-C(R 3b)R 4,-C(R 3b)OR, 4 -C(R 3b)W 3,-C(R 3b)OW 3-sup (R(R 4))或-C(R 3b)(N(R 4)(R 4)); R 4是-H,或1至18个碳原子的烷基,2至18个碳原子的烯基或2至18个碳原子的炔基; R 5是1-18个碳原子的亚烷基,2-18个碳原子的亚烯基或2-18个碳原子的亚炔基; W 3 是W 或W 5 ; W 4是R 6,-C(R 3b)R 6,-C(R 5) 3b)W 5,-SO 2 R 6或-SO 2 M W 组; W 5是碳环或杂环,其中W 5独立地被O至3个R 2基团取代; M2是0,1或2; 或其药学上可接受的盐。